SQM Stock Analysis: Sociedad Quimica y Minera | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 22.360m USD | 12M Return: 73.4% | US8336351056 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 65.4M
Qual. Beats: 1
Rev. Trend: -52.5%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sociedad Química y Minera de Chile S.A. (SQM) is a Chilean producer of specialty plant nutrients, iodine and its derivatives, lithium products, and industrial chemicals, with operations spanning Latin America, the Caribbean, Europe, North America, Asia, and other international markets. Its business is organized around four core segments: specialty plant nutrition, iodine, lithium, and industrial chemicals.
In specialty plant nutrition, SQM produces potassium nitrate, sodium nitrate, specialty blends, potassium sulfate, and potassium chloride, marketed under brands such as Ultrasol, Qrop, Speedfol, Allganic, Ultrasoline, Prop, and Prohydric. The iodine segment supplies medical, pharmaceutical, LCD/LED, and nutrition applications, including x-ray contrast media and iodized salt. The lithium segment produces lithium carbonate and lithium hydroxide for battery cathodes, alongside lithium chloride and derivatives used in glass, ceramics, and metal alloys. Industrial chemicals, including sodium nitrate, potassium nitrate, solar salts, and potassium chloride, serve glass, explosives, pyrotechnics, oil drilling, food processing, and solar power storage markets.
SQM was founded in 1926 and is headquartered in Santiago, Chile. As a large-cap Materials company in the Fertilizers & Agricultural Chemicals sub-industry, it derives its primary commercial advantage from natural resource extraction in the Chilean Atacama region, which holds some of the worlds highest-grade lithium and nitrate reserves.
- Lithium prices fall on Chinese EV demand slowdown
- Chile royalty reform caps long-term lithium margins
- Iodine and specialty plant nutrients revenue stabilizes earnings
| Net Income: 1.39b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 12.38 > 1.0 |
| NWC/Revenue: 69.75% < 20% (prev 85.26%; Δ -15.51% < -1%) |
| CFO/TA 0.17 > 3% & CFO 2.75b > Net Income 1.39b |
| Net Debt (1.03b) to EBITDA (2.97b): 0.35 < 3 |
| Current Ratio: 2.61 > 1.5 & < 3 |
| Outstanding Shares: last quarter (285.6m) vs 12m ago 0.01% < -2% |
| Gross Margin: 42.16% > 18% (prev 26.78%; Δ 15.38% > 0.5%) |
| Asset Turnover: 47.95% > 50% (prev 36.71%; Δ 11.24% > 0%) |
| Interest Coverage Ratio: 13.23 > 6 (EBIT TTM 2.64b / Interest Expense TTM 199.5m) |
| A: 0.28 (Total Current Assets 7.63b - Total Current Liabilities 2.93b) / Total Assets 16.6b |
| B: 0.28 (Retained Earnings 4.61b / Total Assets 16.6b) |
| C: 0.19 (EBIT TTM 2.64b / Avg Total Assets 14.1b) |
| D: 0.79 (Book Value of Equity 6.29b / Total Liabilities 7.94b) |
| Altman-Z'' = 4.86 = AA |
| DSRI: 1.30 (Receivables 1.29b/623.1m, Revenue 6.74b/4.23b) |
| GMI: 0.64 (GM 26.78% / 42.16%) |
| AQI: 2.08 (AQ_t 0.23 / AQ_t-1 0.11) |
| SGI: 1.59 (Revenue 6.74b / 4.23b) |
| TATA: -0.08 (NI 1.39b - CFO 2.75b) / TA 16.6b) |
| Beneish M = -2.05 (Cap -4..+1) = BB |
As of August 29, 2026, the stock is trading at USD 78.63 with a total of 893,875 shares traded. Over the past week, the price has changed by -4.06%, over one month by +17.59%, over three months by -6.45% and over the past year by +73.38%.
Current recommended Stop Loss: 73.90 (which is 6% or 1.7 ATR below the current price).
Sociedad Quimica y Minera has received a consensus analysts rating of 3.94. Therefore, it is recommended to buy SQM.
- StrongBuy: 6
- Buy: 4
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 85.6 | 8.8% |
P/E Trailing = 16.3083
P/E Forward = 12.5945
P/S = 3.3247
P/B = 3.585
P/EG = 0.3661
Revenue TTM = 6.74b USD
EBIT TTM = 2.64b USD
EBITDA TTM = 2.97b USD
Long Term Debt = 4.22b USD (from longTermDebt, last fiscal year)
Short Term Debt = 455.1m USD (from shortTermDebt, last quarter)
Debt = 5.37b USD (from shortLongTermDebtTotal, last quarter) + Leases 73.0m
Net Debt = 1.03b USD (calculated: Debt 5.37b - CCE 4.33b)
Enterprise Value = 23.4b USD (22.4b + Debt 5.37b - CCE 4.33b)
Interest Coverage Ratio = 13.23 (Ebit TTM 2.64b / Interest Expense TTM 199.5m)
EV/FCF = 12.03x (Enterprise Value 23.4b / FCF TTM 1.94b)
FCF Yield = 8.31% (FCF TTM 1.94b / Enterprise Value 23.4b)
FCF Margin = 28.87% (FCF TTM 1.94b / Revenue TTM 6.74b)
Net Margin = 20.61% (Net Income TTM 1.39b / Revenue TTM 6.74b)
Gross Margin = 42.16% ((Revenue TTM 6.74b - Cost of Revenue TTM 3.90b) / Revenue TTM)
Gross Margin QoQ = 51.06% (prev 44.23%)
Tobins Q-Ratio = 1.41 (Enterprise Value 23.4b / Total Assets 16.6b)
Interest Expense / Debt = 3.72% (Interest Expense 199.5m / Debt 5.37b)
Taxrate = 37.65% (928.4m / 2.47b)
NOPAT = 1.65b (EBIT 2.64b * (1 - 37.65%))
Current Ratio = 2.61 (Total Current Assets 7.63b / Total Current Liabilities 2.93b)
Debt / Equity = 0.85 (Debt 5.37b / totalStockholderEquity, last quarter 6.29b)
Debt / EBITDA = 0.35 (Net Debt 1.03b / EBITDA 2.97b)
Debt / FCF = 0.53 (Net Debt 1.03b / FCF TTM 1.94b)
Total Stockholder Equity = 5.83b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.88% (Net Income 1.39b / Total Assets 16.6b)
RoE = 23.82% (Net Income TTM 1.39b / Total Stockholder Equity 5.83b)
RoCE = 26.27% (EBIT 2.64b / Capital Employed (Equity 5.83b + L.T.Debt 4.22b))
RoIC = 11.95% (NOPAT 1.65b / Invested Capital 13.8b)
WACC = 7.88% (E(22.4b)/V(27.7b) * Re(9.21%) + D(5.37b)/V(27.7b) * Rd(3.72%) * (1-Tc(0.38)))
Discount Rate = 9.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -41.82 | Cagr: 0.0%
[DCF] Terminal Value 75.44% ; FCFF base≈1.94b ; Y1≈1.95b ; Y5≈2.07b
[DCF] Fair Price = 218.1 (EV 32.2b - Net Debt 1.03b = Equity 31.1b / Shares 142.8m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 3.55 | # QB: 1
Revenue Correlation: -52.45 | Revenue CAGR: -13.54% | SUE: 4.0 | # QB: 2
EPS current Quarter (2026-09-30): EPS=2.12 | Chg30d=-2.95% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=7.30 | Chg30d=+9.06% | Revisions=+0% | GrowthEPS=+254.2% | GrowthRev=+70.8%
EPS next Year (2027-12-31): EPS=7.07 | Chg30d=+1.91% | Revisions=+22% | GrowthEPS=-3.1% | GrowthRev=+2.0%
[Analyst] Revisions Ratio: +19% (up=8, down=5)